Junshi licenses COVID-19 antibody tech from Lonza

China’s Junshi Biosciences has licensed technology to produce an antibody against COVID-19 from Swiss biotechnology firm Lonza.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

US to pay Pfizer nearly $2bn for COVID-19 vaccine supply

23 July 2020 Pfizer and its German partner BioNTech will receive nearly $2 billion from the US in exchange for the supply of 100 million doses of an experimental coronavirus vaccine.

Generics

Gilead agrees 127-country remdesivir licence with generic makers

14 May 2020 Gilead has agreed to license its antiviral remdesivir to five generic makers for distribution during the COVID-19 pandemic.

Biotechnology

ERS Genomics signs CRISPR deal with Lonza

14 December 2018 ERS Genomics has signed a deal with Swiss company Lonza Pharma & Biotech to provide access to CRISPR/Cas9 technology.

More on this story

Americas

US to pay Pfizer nearly $2bn for COVID-19 vaccine supply

23 July 2020 Pfizer and its German partner BioNTech will receive nearly $2 billion from the US in exchange for the supply of 100 million doses of an experimental coronavirus vaccine.

Generics

Gilead agrees 127-country remdesivir licence with generic makers

14 May 2020 Gilead has agreed to license its antiviral remdesivir to five generic makers for distribution during the COVID-19 pandemic.

Biotechnology

ERS Genomics signs CRISPR deal with Lonza

14 December 2018 ERS Genomics has signed a deal with Swiss company Lonza Pharma & Biotech to provide access to CRISPR/Cas9 technology.

More on this story

Americas

US to pay Pfizer nearly $2bn for COVID-19 vaccine supply

23 July 2020 Pfizer and its German partner BioNTech will receive nearly $2 billion from the US in exchange for the supply of 100 million doses of an experimental coronavirus vaccine.

Generics

Gilead agrees 127-country remdesivir licence with generic makers

14 May 2020 Gilead has agreed to license its antiviral remdesivir to five generic makers for distribution during the COVID-19 pandemic.

Biotechnology

ERS Genomics signs CRISPR deal with Lonza

14 December 2018 ERS Genomics has signed a deal with Swiss company Lonza Pharma & Biotech to provide access to CRISPR/Cas9 technology.